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Abstract
Despite the well-known increased risk to develop non-melanoma skin cancer (NMSC) due to the long-term immunosuppression,
data about melanoma incidence and prognosis in solid organ transplanted patients are still debated. Literature studies report a
relative risk for melanoma varying from 1.2 and 5.8 in different solid organ recipients, probably as a consequence of the difference
in immunosuppressive treatments and endogenous and exogenous risk factors. Here we report data about melanoma incidence,
prognosis and clinicopathological characteristics in a series of 686 kidney transplant recipients. In this series, melanoma incidence
was 3.5%; most cases were represented by in situ or thin melanomas mainly related to sun exposure, and the prognosis of our patients
was good except for only one case with a progressive disease. Our experience confirms the importance of a regular dermatological
follow-up and of education to correct sun exposure even in transplanted patients.
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1. Background
The crucial role of long-term immunosuppressive
treatment as a promoter for malignancy has been exten-
sively established in literature (1), and the increased risk for
non-melanoma skin cancer (NMSC) in solid organ trans-
plant recipients is well known (2, 3).
Conversely, data about melanoma incidence and be-
haviour in transplanted patients are still debated, despite
the fact that the impact of the immune system on the on-
set and progression of this cancer has been clearly demon-
strated (4, 5).
A large analysis performed on an Australian cohort of
kidney transplant recipients reported a melanoma inci-
dence of almost 1% closely related to iatrogenic immuno-
suppression and confined to the period of transplant func-
tion (1). Therefore, a systematic review was recently per-
formed on a 20 cohort study (6), identifying an aggregate
relative risk (RR) for melanoma of 2.71 among transplanted
patients; this risk was higher (5.27) for liver and heart recip-
ients and lower (2.54) for kidney recipients, probably due
to the differences in immunosuppressive regimens. How-
ever, several differences have been demonstrated in vari-
ous studies and the RR ranged from 0.8 (7) to 5.80 (8), prob-
ably due to the heterogeneity of the inclusion criteria and
the follow-up length and to the variability of the ethnic and
geographic origin of patients. The well-known risk factors
for melanoma such as fair skin, presence of atypical nevi,
family history for melanoma, and personal history of sun-
burns could also play a crucial role creating a favourable
substrate on which immunosuppression acts as a trigger-
ing factor.
Here we revised our series of kidney transplant recipi-
ents undergoing a regular dermatological follow-up with
the aim of evaluating the melanoma incidence within this
group of patients, its characteristics, and the possible re-
lationship between the onset of this tumour and eventual
exogenous and endogenous risk factors.
Clinical outcome was also evaluated to establish the
possible immunosuppression impact on the disease pro-
gression.
2. Methods
2.1. Patients
A total of 686 kidney transplant recipients who under-
went a regular dermatological follow-up were included in
this study. Dermatological consultations were performed
between April 1997 and December 2016. Our sample con-
sisted in 401 males and 285 females with a median age of
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50 years at transplantation and of 60 at the last follow-
up visit and a median duration of immunosuppression of
8.9 years. Clinical information about the patients’ endoge-
nous and exogenous risk factors for skin tumours were
recorded and a complete dermatological examination was
performed at each scheduled visit. We collected, also, in-
formation about immunosuppressive schedules which the
patients had undergone.
3. Results
3.1. Clinical Characteristics
The number of the patients who developed a cuta-
neous melanoma in the post-transplantation period was
24 accounting for 3.5% of our series. Seventeen patients
were males and 7 females, with a median age at melanoma
diagnosis of 57 years (ranging from 36 to 78). For these
patients, the median age at transplantation was 49 years
(ranging from 25 to 64), and the median time of immuno-
suppression was 13 years (ranging from 3 to 22); the median
duration of the dermatological follow-up was 8.9 years.
The median time of melanoma onset from transplantation
was 5.3 years (ranging from 0.7 to 14.6). Interestingly, 2
out of 24 patients developed multiple melanomas. One
out of these developed a second melanoma 13 months af-
ter the first diagnosis, whereas the other one developed 3
melanomas after 19 and 53 months from the first diagnosis,
respectively. Clinical data of these patients are reported in
Table 1.
Moreover, 4 patients affected by melanoma developed
also a NMSC. All these lesions were diagnosed as basal cell
carcinoma (BCC); in two cases, the onset of BCC preceded
melanoma diagnosis, while in the other two it occurred
subsequently.
3.2. Histology
Eleven out of 24 of total excised melanomas were his-
tologically in situ melanomas; the median Breslow’s thick-
ness of other lesions was 1.12 mm (ranging from 0.5 to 4
mm). Data about histological characteristics are summa-
rized in Table 2.
3.3. Risk Factors
The skin phototype predominantly represented in our
series (66.6%) was III according to the characteristics of the
patients pertaining to our geographical area. Two patients
reported a history of sunburns at a young age and the other
6 reported frequent sun exposure without photoprotec-
tion. Two patients had working outdoor activities, whereas
nobody reported family history of melanoma. We found
no significant correlation between the type of immuno-
suppressive schedule and melanoma onset.
From the transplanted patients affected by melanoma,
of our series, only one developed metastatic melanoma
with lung and distant nodal metastases.
4. Discussion
It has been demonstrated that the immune surveil-
lance plays a fundamental role in the pathogenesis of
melanoma (4), as confirmed by the importance of im-
munotherapeutic approach in the treatment of advanced
stages of this disease (9). However, while data concerning
the higher risk of NMSC after transplantation are well es-
tablished (2, 3, 10), not all authors agree about the increase
in melanoma risk in transplant recipients (1, 6-12).
In a previous review of our series (13), the 3.9% of kid-
ney recipients who underwent a regular dermatological
follow-up suffered from melanoma; the percentage of pa-
tients affected by NMSC in the same series was 24.8%. Here,
a series significantly increased in number and a longer
follow-up enabled us to identify a percentage of patients
affected by melanoma accounting for 3.5%. In literature,
the pick of melanoma onset in immunosuppressed pa-
tients is reported during the second year from transplan-
tation (1); on the contrary, in our experience the median
time of melanoma onset was 5.3 years, suggesting a po-
tential role of cumulative low-dose immunosuppression.
Moreover, even if cyclosporine and/or azatyoprine-based
immunosuppressive regimens showed a significant corre-
lation with the risk of developing skin cancer in most pub-
lished studies (14-17), we did not find any significant corre-
lation with the treatment schedule.
We think that endogenous and exogenous risk factors
can play a major role in the pathogenesis of melanoma
and, also, in transplanted patients. Differences in skin
phototype and in UV radiation exposure, as well as in the
ethnic and geographical origin of transplanted patients
could explain differences in melanoma prevalence among
the transplanted population in different countries (1, 6-8,
12, 18), justifying the fact that in our series, the incidence
of melanoma is higher than what is described in other
large studies recently published (7). In our series, most pa-
tients showed a phototype III, in accordance with their ori-
gin from the Mediterranean area; however, almost half of
them reported previous significant sun exposure for recre-
ational reasons or outdoor work, suggesting that immuno-
suppression could be a simple trigger on a pre-existing
condition of susceptibility. This hypothesis is supported
by the onset of multiple melanomas in two of our patients
and by the fact that in both, there was a concordance be-
tween sites in which the lesions arise. The site concordance
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Table 1. Clinical Characteristics of Transplanted Patients Affected by Multiple Melanomas
Gender Site Istological Type Breslow Time from Transplantation Time from First Diagnosis
M Foot ALM 4 16.9 y 1st melanoma
Foot ALM 0.8 18 y 13 mo 2nd melanoma
F Trunk SSM In situ 5.9 y 1st melanoma
Trunk SSM In situ 7.4 y 18 mo 2nd melanoma
Trunk LMM 0.6 10.2 y 52 mo 3th melanoma
Table 2. Clinical and Histological Characteristics of Melanomas Diagnosed in Trans-
planted Patients
Variable Value
Gender
M 17
F 7
Age 57 y (range 36 - 78)
Site
Trunk 11
Upper limbs 1
Lower limbs 7
Foot 4
Head 3
Other 1
Histological type
SSM 19
NM 1
ALM 4
LMM 2
Mucosal 1
Breslow thickness 1.12 mm (range 0.5 - 4 mm)
Abbreviations: ALM, acral-lentiginous melanoma; LMM, lentigo maligna
melanom; NM, nodular melanoma; SSM, superficial spreading melanoma.
for patients affected by multiple melanomas justify, in fact,
the assumption that the risk is mainly related to the pre-
vious UV damage (11, 19). The role of the photo exposition
is also confirmed by the diagnosis of BCC in other four pa-
tients.
In our experience, more than 45% of our patients (11/24)
had an in-situ melanoma; for other patients, the median
Breslow thickness was relatively low with a high preva-
lence of Superficial Spreading Melanoma. These observa-
tions support, on the one hand, the relatively low aggres-
siveness of melanomas diagnosed in kidney transplanted
patient; on the other hand, the major role of dermatolog-
ical follow-up. In most patients, in fact, the diagnosis was
made incidentally during a routinely programmed visit.
Literature data regarding the clinical course of
melanoma developed in the post-transplant period are
scanty. However, the thickness of the primary lesion and
the known prognostic factors seems to regulate the course
of the disease even in transplanted patients (20) and the
outcome of patients with thicker melanoma is worse than
that of patients with thinner lesions. No deaths are in
fact reported for transplant recipients with in situ or thin
melanomas (21). Also, in our experience, the only one
patient who developed a progressive disease was affected
by a 4-mm ALM that metastasised to distant lymph node
and lung.
Future studies are needed to better characterize the
melanoma risk and the outcome in transplant recipients.
However, also in this group of patients, early diagnosis is
critical and dedicated dermatologic follow-up programs
are fundamental; in view of the role of sun exposure, we
also underline the importance of the constant education
to the photoprotection in transplanted patients.
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